Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety of Lansoprazole/Domperidone in GERD
NCT03355170Phase 4Withdrawn
- Sponsor
- Neutec Group
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lansoprazole + domperidone in gastroesophageal reflux disease (GERD), sponsored by Neutec Group. Planned start Mar 2018; status: withdrawn.
02
Drugs
lansoprazole + domperidone
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03355170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355170.